TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20368196
Drug: Ongoing glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing glucose-lowering treatment (C-group)
Study: 17990195
Drug: SHR-5 extract
Normalized name: Capsicum extract 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-5 extract (340 mg/day)
Study: 17990195
Drug: SHR-5 extract
Normalized name: Capsicum extract 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-5 extract (680 mg/day)
Study: 1922220
Drug: 283 mg
Normalized name: Docusol 283 MG per 5 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 283 mg of aspirin
Study: 6420959
Drug: Ibuprofen (instead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (instead of steroids) with azathioprine and ATGAM for three months
Study: 6420959
Drug: Azathioprine, high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine, high doses of prednisolone, and ATGAM for three months
Study: 6420959
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (Ibuprofen)
Study: 31006972
Drug: Nondrug ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondrug ultrasound (US) therapy
Study: 25480588
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus 75‐100 mg aspirin
Study: 25480588
Drug: Warfarin only
Normalized name: Warfarin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin only
Study: 21771042
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training programme (listening to a 13-minute relaxation programme daily)
Study: 18185146
Drug: Lutein administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein administration
Study: 15865225
Drug: PEG-IFN 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-IFN 1.5 microg/kg/week plus RBV 400 mg twice daily (arm A)
Study: 9634050
Drug: Selenium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium treatment (200 microg daily)
Study: 26581111
Drug: E6005 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6005 ointment (0.01% to 0.2%) in Study 001
Study: 26581111
Drug: E6005 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6005 ointment (0.01% to 0.2%) in Study 101
Study: 26581111
Drug: E6005 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6005 ointment (0.01% to 0.2%) in both studies
Study: 25332324
Drug: Daily snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snack made from green leafy vegetables, fruit, and milk (treatment group)
Study: 17660154
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg albuterol
Study: 17660154
Drug: 0.62 mg
Normalized name: karaya gum 0.62 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.62 mg albuterol
Study: 9098301
Drug: Single intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraoperative application of 0.2 mg/ml mitomycin C for 3 minutes
Study: 9098301
Drug: Single intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraoperative application of 0.4 mg/ml mitomycin C for 3 minutes
Study: 9098301
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C eye drops 0.2 mg/ml three times daily for 7 days
Study: 9098301
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C eye drops 0.4 mg/ml three times daily for 14 days
Study: 2713212
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion at 0.07 mg kg‐1 min‐1
Study: 2713212
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion at 0.03 mg kg‐1 min‐1
Study: 2713212
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion at 0.005 mg kg‐1 min‐1
Study: 946338
Drug: Pimozide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (2 mg initially, then 1 mg/day)
Study: 946338
Drug: Fusaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusaric acid (600 mg/day)
Study: 30169244
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg three times daily until 32 weeks and 0 days' gestation or delivery
Study: 24513094
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with timolol 0.5%
Study: 24513094
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with brimonidine 0.2%
Study: 22452789
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion after a 4-day high sodium diet (300 mmol sodium/day)
Study: 22452789
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion after a 4-day low sodium diet (30 mmol sodium/day)
Study: 22452789
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion during high sodium intake
Study: 16080835
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg qd)
Study: 16080835
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (both bisoprolol and carvedilol)
Study: 10426128
Drug: lonidamine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: lonidamine (450 mg daily p.o. until progression)
Study: 10426128
Drug: vindesine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: vindesine (3 mg/m2/daily i.v. weekly for 4 weeks and then every 2 weeks until progression)
Study: 10426128
Drug: lonidamine +
Normalized name: lonidamine
DrugBank: Lonidamine (DB06266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lonidamine + vindesine (at the same dose and schedule)
Study: 10426128
Drug: supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: supportive therapy only
Study: 7493300
Drug: Recombinant interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interferon-alpha 2a (IFN-alpha 2a) starting dose 6 MU, adjusted based on ALT response
Study: 31753866
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training (3 weekly sessions of 35 min moderate intensity walking/running and 25 min resistance training until delivery)
Study: 2193560
Drug: Adenosine 12
Normalized name: adenosine 12 MG in 4 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 12 mg
Study: 27759898
Drug: Adenosine 18
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 18 mg
Study: 27759898
Drug: Adenosine 24
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 24 mg
Study: 27759898
Drug: Adenosine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (all doses)
Study: 27759898
Drug: Adenosine (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (doses 18 mg and 24 mg)
Study: 26423650
Drug: BMS-663068 400
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-663068 400 mg twice daily
Study: 26423650
Drug: BMS-663068 800
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-663068 800 mg twice daily
Study: 26423650
Drug: BMS-663068 600
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-663068 600 mg once daily
Study: 26423650
Drug: BMS-663068 1200
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-663068 1200 mg once daily
Study: 15126548
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg recombinant human TSH (rhTSH)
Study: 11431171
Drug: t.i.d. tiagabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: t.i.d. tiagabine (three times daily)
Study: 11431171
Drug: b.i.d. tiagabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. tiagabine (twice daily)
Study: 1572037
Drug: Transient ST
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transient ST segment abnormalities during daily activities
Study: 29272068
Drug: Camelina Sativa
Normalized name: CAMELINA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camelina Sativa Oil (10 g d‐1 ALA)
Study: 15127083
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg lorazepam
Study: 15512028
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium and low-dose aspirin
Study: 2195514
Drug: Piezoelectric inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piezoelectric inhalation device
Study: 2195514
Drug: Metered-dose aerosols
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose aerosols
Study: 28629318
Drug: 0.05% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% chlorhexidine oral rinse solution
Study: 28629318
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral hygiene care (Control)
Study: 28629318
Drug: Functional Oral
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Oral Intake Scale (FOIS)-level
Study: 21487057
Drug: Betamethasone 12
Normalized name: Betamethasone 120 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 12 mg intramuscularly for two consecutive days
Study: 8050140
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with a combination of n‐3 (marine oil) and n‐6 (evening primrose oil) essential fatty acids
Study: 2903876
Drug: Doxepin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (25 mg)
Study: 2903876
Drug: Desipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (25 mg)
Study: 19627681
Drug: Physiotherapy intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy intervention including manual therapy, exercises, and psychological strategies, tailored individually with a maximum of six treatments over an 8-week period.
Study: 28639229
Drug: MHAA4549A (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAA4549A (400, 1200, or 3600 mg)
Study: 28639229
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg twice daily from days 7 to 11)
Study: 27632919
Drug: Prescription omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription omega-3 acid ethyl esters (O3AEE) 1 g/d
Study: 17323547
Drug: Parenteral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral intake of 10% glucose solution with minerals (Group B)
Study: 12673731
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and continuous-infusion doxorubicin (n = 26 patients)
Study: 8679045
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA) with antiemetic prophylaxis (2.5 mg DHBP)
Study: 8679045
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA) without antiemetic prophylaxis
Study: 8679045
Drug: Balanced Anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Anaesthesia with antiemetic prophylaxis (2.5 mg DHBP)
Study: 8679045
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA) with DHBP
Study: 6369557
Drug: mebendazole 500
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mebendazole 500 mg thrice daily for 21 days
Study: 6369557
Drug: mebendazole 500
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mebendazole 500 mg thrice daily + levamisole hydrochloride 2.5 mg/kg weekly for 3 weeks
Study: 31591650
Drug: 14 mg/d
Normalized name: nicotine 14 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg/d lactolycopene for 12 weeks
Study: 31562797
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg respectively every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks)
Study: 31562797
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks) plus ipilimumab-matched placebo
Study: 31562797
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg every 3 weeks for four doses) plus nivolumab-matched placebo
Study: 24383478
Drug: Erythromycin IV
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin IV 150 mg
Study: 24383478
Drug: Morphine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine IV 0.05 mg/kg BW
Study: 11536417
Drug: Sleep therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep therapy programme (six-session group programme including stimulus control therapy, relaxation training, and other strategies)
Study: 11536417
Drug: Sleep therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep therapy programme
Study: 9604143
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg KW-4679 (single-dose trial)
Study: 9604143
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg KW-4679 (multiple-dose trial)
Study: 31413313
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and mTOR inhibitor (second-line treatment)
Study: 31413313
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and mTOR inhibitor (third-line treatment)
Study: 25135348
Drug: Intravenous glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose-insulin-potassium (GIK) therapy
Study: 24568002
Drug: Beech Brook
Normalized name: ALLERGENIC EXTRACT, BEECH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beech Brook Therapy Assessment Instrument
Study: 17157592
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% topical therapy with reduced drop-skin contact (eye 1)
Study: 17157592
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% topical therapy (fellow eye)
Study: 14581436
Drug: MMC in
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC in combination with local microwave-induced hyperthermia
Study: 10977126
Drug: Gelfoam disc
Normalized name: Sus scrofa intervertebral disc preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelfoam disc impregnated with 0.60 mg of tropicamide racemate and 1.7 mg of 1‐phenylephrine hydrochloride
Study: 10977126
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered drops (phenylephrine hydrochloride 2.5% solution and tropicamide 1% solution)
Study: 16741368
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (once daily SLIT) with 10 days updosing (T1), 20 days maintenance treatment (T2), and 2 consecutive months on maintenance treatment (T3 and T4)
Study: 16741368
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with placebo updosing (T1), placebo maintenance (T2), initiated active treatment at T3, and continued active treatment until the end of the study (T4)
Study: 16741368
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (once daily SLIT)
Study: 14703417
Drug: Aprotinin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (loading dose of 2 x 10(6) KIU followed by continuous infusion of 0.5 x 10(6) KIU/h)
Study: 8204123
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and subcutaneous heparin
Study: 8204123
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and intravenous heparin
Study: 1555479
Drug: Front-loaded, weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-loaded, weight-adjusted rt-PA and intravenous heparin
Study: 1555479
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of streptokinase and rt-PA and intravenous heparin
Study: 3921279
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (60 mg/24 hr)
Study: 31007691
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (fish oil) 1500 mg/d
Study: 26636393
Drug: Heparin management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin management
Study: 22569432
Drug: Oral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine (LC) supplementation, 250 mg tablets three times a day for eight weeks
Study: 18823152
Drug: Testosterone modified
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone modified to match levels of younger men for 6 weeks; conversion of testosterone to estradiol blocked; production of testosterone blocked; placebo (no treatment)
Study: 22016074
Drug: Shock therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock therapy
Study: 8953409
Drug: Liposomal ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal ointment
Study: 8953409
Drug: Plain drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain drug ointment
Study: 8953409
Drug: Liposomal formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal formulations with ultrasound
Study: 9431834
Drug: Benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 20 mg
Study: 2007326
Drug: Benazepril 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 2, 5, and 10 mg
Study: 2007326
Drug: Open-label Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label Hydrochlorothiazide (25 mg/day) added to benazepril, hydrochlorothiazide, or placebo
Study: 31420350
Drug: Reference erythropoiesis-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference erythropoiesis-stimulating agents
Study: 21302117
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups with saline irrigation of 400 ml or more
Study: 10481417
Drug: Propofol injected
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol injected at a rate of 800 ml/hr after fentanyl 100 micrograms
Study: 10481417
Drug: Propofol injected
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol injected at a rate of 1 ml/s after fentanyl 100 micrograms
Study: 1681840
Drug: Midazolam 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.08 mg kg‐1
Study: 31648845
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy (ambrisentan and tadalafil)
Study: 31648845
Drug: Pooled monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled monotherapy (ambrisentan or tadalafil)
Study: 25950389
Drug: Preoperative subpterygial
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative subpterygial Mitomycin C injection (0.1mL 0.015% MMC)
Study: 25950389
Drug: Intraoperative subpterygial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative subpterygial Mitomycin C injection (0.1mL 0.015% MMC)
Study: 24321802
Drug: SMART regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART regimen (budesonide-formoterol 200 μg and 6 μg per actuation, twice daily, plus as needed)
Study: 17067979
Drug: Pycnogenol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (50 mg capsules, 3 times daily for a total of 150 mg daily) for 8 weeks
Study: 15526380
Drug: Selenium (1.156x10(‐7)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (1.156x10(‐7) mol/L) for 6 h in vitro or selenium-yeast (200 microg/d) for 8-12 wk
Study: 15526380
Drug: Chronic hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic hepatitis patients (without selenium treatment)
Study: 7011467
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of dipyridamole in combination with 30 mg (0.5 mg/kg) of acetylsalicylic acid (ASA)
Study: 7011467
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of dipyridamole in combination with 50 mg (0.8 mg/kg) of acetylsalicylic acid (ASA)
Study: 7011467
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of dipyridamole in combination with 160 mg (2.6 mg/kg) of acetylsalicylic acid (ASA)
Study: 7011467
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of dipyridamole in combination with 330 mg (5.7 mg/kg) of acetylsalicylic acid (ASA)